

## Research Article

# Association of Transferable Quinolone Resistance Determinant *qnrB19* with Extended-Spectrum $\beta$ -Lactamases in *Salmonella* Give and *Salmonella* Heidelberg in Venezuela

Fanny González and María Araque

Laboratorio de Microbiología Molecular, Departamento de Microbiología, Facultad de Farmacia y Bioanálisis, Universidad de Los Andes, Mérida 5101, Venezuela

Correspondence should be addressed to María Araque; [araquemc@ula.ve](mailto:araquemc@ula.ve)

Received 6 July 2013; Revised 13 August 2013; Accepted 29 August 2013

Academic Editor: Michael McClelland

Copyright © 2013 F. González and M. Araque. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Four nontyphoidal *Salmonella* strains with resistance to extended-spectrum cephalosporins and nonclassical quinolone resistance phenotype were studied. Two *S. Give* were isolated from pediatric patients with acute gastroenteritis, and two *S. Heidelberg* were recovered from raw chicken meat. Phenotypic characterization included antimicrobial susceptibility testing and detection of extended-spectrum  $\beta$ -lactamases (ESBLs) by the double-disc synergy method. The detection of quinolone resistance-determining regions (QRDR) of *gyrA*, *gyrB*, and *gyrC* genes, *bla*<sub>ESBLs</sub> genes, and plasmid-mediated quinolone resistance (PMQR) determinants was carried out by molecular methods. Plasmid analysis included Southern blot and restriction patterns. Transferability of resistance genes was examined by transformation. *bla*<sub>TEM-1</sub> + *bla*<sub>SHV-12</sub> genes were detected in *S. Give* SG9611 and *bla*<sub>TEM-1</sub> + *bla*<sub>CTX-M-2</sub> in the other three strains: *S. Give* SG9811, *S. Heidelberg* SH7511, and SH7911. Regardless of origin and serovars, the *qnrB19* gene was detected in the 4 strains studied. All determinants of resistance were localized in plasmids and successfully transferred by transformation. This study highlights the circulation of *qnrB19* associated with *bla*<sub>TEM-1</sub>, *bla*<sub>SHV-12</sub>, and *bla*<sub>CTX-M-2</sub> in *S. Give* and *S. Heidelberg* in Venezuela. The recognition of factors associated with increasing resistance and the study of the molecular mechanisms involved can lead to a more focused use of antimicrobial agents.

## 1. Introduction

Nontyphoidal *Salmonella* (NTS) are one of the major causes of foodborne infections related to the ingestion of contaminated animal food products in humans [1]. In most cases, these infections are confined to the gastrointestinal tract and are self-limiting. However, for immunocompromised and/or elderly patients, as well as for invasive or prolonged infections, antibiotic treatment is recommended [2]. Fluoroquinolones and extended-spectrum  $\beta$ -lactams are the first-choice agents for these cases but the increase of the multidrug resistance (MDR) *Salmonella* strains reduces the available treatment options [1–5].

The emergence of *Salmonella* spp. isolates that display resistance to extended-spectrum  $\beta$ -lactams is mediated by

plasmids and is an increasing public health concern [3–5]. The resistance to fluoroquinolones is typically mediated by alterations in the target enzymes DNA gyrase and topoisomerase IV or changes in drug entry and efflux. Also, three plasmid-mediated mechanisms conferring decreased susceptibility to ciprofloxacin have been recently described: QepA efflux, Aac(6′)-Ib-cr aminoglycoside acetyltransferase, and QNR proteins (*qnrA*, *qnrB*, *qnrC*, *qnrD*, and *qnrS*) [6, 7]. The *qnr* determinants encode pentapeptide repeat proteins, which are thought to bind to DNA gyrase, protecting it from quinolones; *aac(6′)-Ib-cr* encodes a variant aminoglycoside acetyltransferase that modifies those fluoroquinolones that have a piperazinyl moiety, such as ciprofloxacin and norfloxacin, while *qepA* encodes a major facilitator efflux pump [6–8].

Several studies have shown the coexistence of plasmid-mediated quinolone resistance (PMQR) determinants with extended-spectrum  $\beta$ -lactamases (ESBL) on the same plasmid or cross-species/genera transferability of the plasmids [6, 9]. Selective pressure exerted by fluoroquinolones may be a driving force leading to the emergence and spread of isolates that carry not only PMQR determinants but also ESBL. Thus, close linkage between different resistance determinants may lead to high prevalence of MDR *Salmonella* strains under antibiotic-specific selective pressure [4, 5, 8]. In fact, the emergence of the association between PMQR and ESBL is an issue that narrows the usage of valuable antibiotics in managing NTS infections [1, 5, 9].

Epidemiologic studies of more than 2,300 NTS strains from human cases and animals in North America, Europe, and Asia have reported the prevalence of *qnrA*, *qnrB*, *qnrS*, and *aac(6')-Ib-cr* genes in 0.2%, 1.0%, 2.4%, and 6.4%, respectively [6]. On the other hand, in a previous study carried out by our team from 2005 to 2007 and in 2008, we found a prevalence of *qnrB19* (4.7%) in 117 NTS strains isolated from feces of pediatric patients and raw chicken meat [10]. Nevertheless, molecular and epidemiologic information on mechanisms of resistance in *Salmonella enterica* in Venezuela is scarce [10, 11]. The aim of this study was to determine the coexistence of PMQR determinant *qnrB19* and ESBL in *S. Give* and *S. Heidelberg* isolates from clinical sample and raw chicken meat in Mérida, Venezuela.

## 2. Materials and Methods

**2.1. *Salmonella* Strains.** In 2011, four NTS strains expressing a remarkable type of multidrug resistance were studied. These strains were selected from a collection of the Molecular Microbiology Laboratory of the Pharmacy and Bioanalysis Faculty of The Andes University, Mérida, Venezuela, based on resistance to extended-spectrum cephalosporins and an unusual quinolone resistance phenotype with reduced susceptibility to ciprofloxacin and associated susceptibility to nalidixic acid. Two *S. Give* (SG9611 and SG9811) were isolated from stool specimens obtained from pediatric patients with acute gastroenteritis, and two *S. Heidelberg* (SH7511 and SH7911) were recovered from raw chicken meat.

**2.2. Antimicrobial Susceptibility Testing.** The resistance patterns were determined by the standard plate agar dilution method, according to the Clinical and Laboratory Standards Institute (CLSI) guidelines [12]. The antimicrobial agents tested included (Sigma-Aldrich, St Louis, MO): cefoxitin, cefotaxime, cefotaxime-clavulanic acid, ceftazidime, ceftazidime-clavulanic acid, aztreonam, imipenem, meropenem, ertapenem, nalidixic acid, ciprofloxacin, amikacin, gentamicin, and tobramycin. *E. coli* ATCC 25922 was always used for quality control purposes. The ESBL phenotype was detected by the double-disc synergy (DDS) method [12].

### 2.3. Determination of Antimicrobial Resistance Genes and Sequence Analysis

**2.3.1. Detection of Mutations in the Topoisomerase Genes *gyrA*, *gyrB*, and *parC*.** PCR was used to amplify the quinolone resistance-determining regions (QRDR) of target genes to identify mutations in each isolate. DNA was prepared, and the QRDR of *gyrA*, *gyrB*, and *parC* were amplified with previously described primers and protocols [13].

**2.3.2. Detection of PMQR.** Screening for *qnrA*, *qnrB*, *qnrS*, *qnrD*, *aac(6')-Ib*, and *qepA* genes was carried out by multiplex and simplex PCR amplifications using a previously described method and specific primers [14, 15].

**2.3.3. Detection of  $\beta$ -Lactamase Genes.** *bla*<sub>TEM</sub>, *bla*<sub>SHV</sub>, and group *bla*<sub>CTX-M</sub> genes were detected by PCR using previously described primers and protocols [16].

All amplification products were purified (PCR-Accuprep kit Bioneer), and their nucleotide sequencing was performed with the 3730XL genetic analyzer (Applied Biosystems, CA, USA). Nucleotide and amino acid sequence alignments were analyzed using the Basic Local Alignment Search Tool (BLAST) suite of programs (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>).

**2.4. Plasmid Analysis.** Plasmid DNA was extracted using the QIAprep spin miniprep kit (Qiagen Inc., USA). The presence of *bla*<sub>ESBLs</sub> and PMQR determinants was ensured using Southern blot analysis on nylon membranes as described for the dot blot hybridization [17]. These plasmids were analyzed by restriction mapping using the HindIII and PstI enzyme (Promega, Madison, WI, USA) to observe the restriction patterns, and the resulting fragment sizes were determined by gel electrophoresis.

**2.5. Transformation Experiment.** ESBL and Qnr-harboring plasmids were transferred into *E. coli* HB101 competent cells by electroporation (Eppendorf model 2510, Germany) using approximately 0.5  $\mu$ g of the plasmid DNA preparation under conditions recommended by manufacturer. Mueller Hinton agar supplemented with 8  $\mu$ g/mL cefotaxime and 0.06  $\mu$ g/mL ciprofloxacin was used for selection of transformants. The presence of *bla*<sub>ESBLs</sub> and *qnr* genes in the transformants was confirmed by antimicrobial susceptibility and PCR assays. Results were compared with those of the corresponding donor strains.

## 3. Results

**3.1. Antimicrobial Susceptibility Testing.** MICs of selected antibiotic for *S. Give* and *S. Heidelberg* strains and their transformants are presented in Table 1. All strains were resistant to all tested extended-spectrum cephalosporins and monobactams. By using clavulanic acid, an 8- to 10-fold reduction of MICs of cefotaxime and ceftazidime was observed. A positive double-disk test also confirmed ESBL

TABLE 1: Antibiotic susceptibility of *qnrB* positive and ESBL-producing *S. Give* and *S. Heidelberg* isolates and their transformants, recipient *E. coli* HB101, and quality control *E. coli* ATCC 25922.

Antibiotics tested	MIC (mg/liter) for									
	S. Give		E. coli transformants		S. Heidelberg		E. coli transformants		E. coli	
	SG9611	SG9811	9611trf	9811trf	SH7511	SH7911	7511trf	7911trf	HB101	ATCC 25922
Cefoxitin	8	8	4	8	8	8	8	8	2	2
Cefotaxime	4	128	8	128	>256	>256	256	128	0.064	0.125
CTX/CLA	0.125	0.25	0.25	0.25	1	0.5	0.25	0.25	0.125	0.125
Ceftazidime	64	32	64	32	32	32	32	32	0.25	0.125
CAZ/CLA	0.25	0.125	0.25	0.25	0.25	0.25	0.125	0.125	0.25	0.125
Aztreonam	16	16	16	32	16	16	16	16	0.25	0.25
Ertapenem	0.064	0.064	0.064	0.064	0.064	0.064	0.032	0.064	0.064	0.032
Imipenem	0.064	0.064	0.064	0.064	0.064	0.064	0.064	0.064	0.032	0.032
Meropenem	0.064	0.032	0.064	0.064	0.064	0.064	0.064	0.064	0.032	0.032
Ciprofloxacin	1	1	1	1	1	1	1	2	0.125	0.015
Nalidixic Acid	8	4	8	4	4	8	4	8	2	1
Amikacin	4	2	2	2	8	2	8	8	0.25	0.25
Gentamicin	4	32	2	32	8	>64	16	64	0.5	1
Tobramycin	16	4	16	2	4	8	2	4	0.5	0.25
Other test DDST	+	+	+	+	+	+	+	+	-	-

CTX/CLA: cefotaxime/clavulanic acid; CAZ/CLA: ceftazidime/clavulanic acid; DDST: double disk synergy test.

production. These strains remained fully susceptible to cefoxitin, carbapenems, and amikacin. *S. Give* SG9811 and *S. Heidelberg* SH7911 were resistant to gentamicin (32  $\mu\text{g}/\text{mL}$  and >64  $\mu\text{g}/\text{mL}$ , resp.) while *S. Give* SG9611 was resistant to tobramycin (16  $\mu\text{g}/\text{mL}$ ).

ESBL and quinolone-resistance-harboring plasmids were successfully transferred by transformation from all parental strains to the recipient *E. coli* HB101 strain. Negligible differences were found among the MICs of the transformants and their *Salmonella* donors. Only *S. Heidelberg* SH7511 and SH7911 strains, showing a phenotype of intermediate susceptibility to gentamicin and tobramycin (8  $\mu\text{g}/\text{mL}$ ), respectively, produced transformant cells (7511trf and 7911trf) clearly defined as resistant to gentamicin (16  $\mu\text{g}/\text{mL}$ ) and sensitive to tobramycin (4  $\mu\text{g}/\text{mL}$ ).

**3.2. Plasmid Analysis.** Plasmid purified from 9811trf, 7511trf and 7911trf of ~19 kb exhibited similar restriction pattern generated by single as well as double digestion HindIII and PstI, whereas p9611trf of ~13 kb had a unique restriction pattern. However, Southern blot experiments confirmed that *bla*<sub>ESBL</sub> and *qnr* alleles were present in all isolated plasmids (data not shown).

**3.3. Detection of  $\beta$ -Lactamases and *qnr* Genes.** PCR amplification, using specific primers for *bla*<sub>TEM</sub>, *bla*<sub>SHV</sub>, and group *bla*<sub>CTX-M</sub>, and sequencing analysis, allowed us to identify *bla*<sub>TEM-1</sub> + *bla*<sub>SHV-12</sub> in *S. Give* SG9611 and *bla*<sub>TEM-1</sub> + *bla*<sub>CTX-M-2</sub> in the other three strains: *S. Give* SG9811, *S. Heidelberg* SH7511, and *S. Heidelberg* SH7911. Regardless of origin and serovars, the *qnrB* gene was detected in the 4 strains studied (Table 2). Sequence analysis of the amplification product revealed the *qnrB19* variant with a 99%

degree of identity, corresponding to the nucleotide sequence reference GenBank accession no. EU432277. No mutations were identified in the QRDR of the *gyrA*, *gyrB*, and *parC* genes.

#### 4. Discussion

Since 2007, we have been reporting the presence of NTS producing gastroenteritis in pediatric patients from urban areas and in asymptomatic children from indigenous communities in Venezuela [11, 18, 19]. In these studies, *Salmonella* strains remained susceptible to cephalosporins and fluoroquinolones. Subsequently, in 2010, *S. Heidelberg* and *S. Enteritidis* strains isolated from food showed production of ESBL not associated with resistance to fluoroquinolones [20]. Recently, we also reported the first description of the occurrence of the PMQR determinant *qnrB19* in serovars Havana, Give, Heidelberg, and Meleagridis in Mérida, Venezuela [10].

In this study, based on the patterns of resistance for  $\beta$ -lactam antibiotic and an unusual quinolone resistance phenotype with decreased susceptibility to ciprofloxacin (MIC: 0.5–1  $\mu\text{g}/\text{mL}$ ) but still susceptible to nalidixic acid (MIC: 4–8  $\mu\text{g}/\text{mL}$ ), we strongly suspect the presence of plasmids harboring *bla*<sub>ESBLs</sub> and *qnr* genes in two different *Salmonella* serovars from clinical sample of pediatric patients and raw chicken meat.

Amplification and sequencing of *bla*<sub>ESBLs</sub> and *qnr* genes revealed the presence of *bla*<sub>TEM-1</sub> + *bla*<sub>SHV-12</sub> in *S. Give* SG9611 and *bla*<sub>TEM-1</sub> + *bla*<sub>CTX-M-2</sub> in other three strains: *S. Give* SG9811, *S. Heidelberg* SH7511, and SH7911, associated in all cases with the *qnrB19* gene as the only determinant responsible for the quinolone phenotype.

The mechanism of the Qnr protective effect is not completely understood [6]. However, it has been proposed that

TABLE 2: Phenotypic and genotypic characteristics of *S. Give* and *S. Heidelberg* isolates and their transformants (trf).

Strain number	Sample	Serovar	Resistance pattern	Plasmid size (kb) <sup>a</sup>	$\beta$ -lactamase type	<i>qnr</i> gene
SG9611	Human	Give	ESBL+, CIP, TOB	13	<i>bla</i> <sub>TEM-1</sub> + <i>bla</i> <sub>SHV-12</sub>	<i>qnrB19</i>
9611trf			ESBL+, CIP, TOB	13	<i>bla</i> <sub>TEM-1</sub> + <i>bla</i> <sub>SHV-12</sub>	<i>qnrB19</i>
SG9811	Human	Give	ESBL+, CIP, GEN	19	<i>bla</i> <sub>TEM-1</sub> + <i>bla</i> <sub>CTX-M-2</sub>	<i>qnrB19</i>
9811trf			ESBL+, CIP, GEN	19	<i>bla</i> <sub>TEM-1</sub> + <i>bla</i> <sub>CTX-M-2</sub>	<i>qnrB19</i>
SH7511	Chicken	Heidelberg	ESBL+, CIP, GEN <sub>I</sub>	19	<i>bla</i> <sub>TEM-1</sub> + <i>bla</i> <sub>CTX-M-2</sub>	<i>qnrB19</i>
7511trf			ESBL+, CIP, GEN	19	<i>bla</i> <sub>TEM-1</sub> + <i>bla</i> <sub>CTX-M-2</sub>	<i>qnrB19</i>
SH7911	Chicken	Heidelberg	ESBL+, CIP, GEN, TOB <sub>I</sub>	19	<i>bla</i> <sub>TEM-1</sub> + <i>bla</i> <sub>CTX-M-2</sub>	<i>qnrB19</i>
7911trf			ESBL+, CIP, GEN	19	<i>bla</i> <sub>TEM-1</sub> + <i>bla</i> <sub>CTX-M-2</sub>	<i>qnrB19</i>

<sup>a</sup>Estimated; ESBL+: extended-spectrum  $\beta$ -lactamase positive; CIP: ciprofloxacin; GEN: gentamicin; GEN<sub>I</sub>: intermediate sensibility to gentamicin; TOB: tobramycin; TOB<sub>I</sub>: intermediate sensibility to tobramycin.

the Qnr proteins interact with DNA gyrase and topoisomerase IV, hindering the action of the quinolones and minimizing their inhibitory effect, while isolates with a *qnr* gene may be less likely to develop topoisomerase mutations than other strains [6–8]. The results of this study agree with these observations. The QRDS of the gyrase and topoisomerase IV genes were screened for the most commonly occurring mutations, but no resistance-associated substitutions were detected.

Although there are few studies reporting the prevalence of *qnr* genes in *Salmonella* isolates from South American countries, alleles belonging to the *qnrB* are the most frequently detected in the *Enterobacteriaceae* family [1, 6], in accordance with the results obtained in this study.

Plasmids with *qnr* genes have been found to cotransfer TEM, SHV, and CTX-M genes. Particularly, the association between QnrB-like determinants and SHV-12, CTX-M-9, CTX-M-14, and CTX-M-15 has been reported in NTS strains [1, 4, 6, 7]. In this study, *qnrB19* and *bla*<sub>TEM-1</sub>, *bla*<sub>SHV-12</sub>, and/or *bla*<sub>CTX-M-2</sub> genes located in plasmids were successfully transferred by transformation to susceptible *E. coli* recipient. Also, the resistance to gentamicin and tobramycin was cotransferred. It is recognized that insertion sequences (IS), as *ISCR1* or *ISEcp1* associated with *qnrB* genes, provide a putative promoter region for the expression of genes encoding resistance to aminoglycosides, trimethoprim, chloramphenicol, and  $\beta$ -lactams [6, 21]. Additionally, the coexistence between *qnr* and aminoglycosides was expected because *qnrB* genes are frequently located in integrons [6, 9]. Regardless that all the four plasmids purified from transformant cells possessed *bla*<sub>TEM-1</sub>, *bla*<sub>SHV-12</sub> or *bla*<sub>CTX-M-2</sub>, and *qnrB19*, only one of these (p9611trf) exhibited differences of size (~13 kb) and a particular restriction pattern. It is possible that the organization of diverse genetic elements that participate in mobilization, transposition, recombination, and resolution, as well as deletion and insertion of DNA, generates variations in size and diversity of plasmid structures.

According to the chronology of isolation and origin of the strains studied here, we believe that the source of the *qnr* gene might not be directly related to the use of quinolone, since these drugs are not prescribed in pediatrics patient, but possibly a coselection of the *qnr*-harboring plasmids could be related to a linkage with other resistance genes carried on the same plasmids (*bla*<sub>ESBLs</sub>). Moreover, fluoroquinolones are

widely used in veterinary medicine and poultry production, and *qnr*-positive NTS isolates could be selected and transmitted to humans through the food chain [22].

Based on several reports, the use of fluoroquinolones in infections caused by *Salmonella* isolates with reduced susceptibility may lead to treatment failures and promote the selection of bacteria with higher-level resistance to quinolone, thereby fostering the effect of others mechanisms of resistance as mutations [5, 7, 8, 23].

The real prevalence of PMQR is usually underestimated as there are no reliable phenotypic methods to detect their presence [4]. Also, clinical isolates harboring PMQR determinants did not show any significant change in their MICs when compared with isolates susceptible to nalidixic acid and negative for presence of *qnr* genes. Hence, it is important to revise fluoroquinolones susceptibility testing practice, since strains with similar phenotype as those described in this study might be undetected in clinical laboratories using traditional phenotypic methods.

While prevalence data from an international survey that included 13 European countries identified the *qnrS* gene in a *Salmonella sp.* collection from human clinical sample and the *qnrD* gene in NTS strains of eight different serovars isolated from animal sources [24], and a Danish study reported the coexistence of *bla*<sub>CTX-M-15</sub> and *bla*<sub>SHV-12</sub> genes in a single plasmid associated with *qnrB2* genes in *S. Concord* and *S. Senftenberg* isolated from human patients [1], our results showed the presence of *qnrB19* associated with *bla*<sub>TEM-1</sub>, *bla*<sub>SHV-12</sub>, and *bla*<sub>CTX-M-2</sub> in *S. Give* and *S. Heidelberg* from pediatric patients and raw chicken meat. Nevertheless, prevalence data should be interpreted with caution, since selection criteria for strains included in surveys could potentially bias the results because many studies have been performed with isolates collected over a short period of time, in the context of an outbreak or strains that are resistant to various antimicrobials agents [6, 22].

Unfortunately, data on the occurrence of ESBL associated with PMQR in NTS strains from South America are scarce. To date, only in Brazil the presence of a *qnrA1* in 100 isolates of *S. Enteritidis* and *qnrB19* in one strain of *S. Corvallis* from poultry origin has been described [25].

Although this study includes few NTS isolates, we could prove the association of transferable quinolone resistance determinant *qnrB19* with extended-spectrum  $\beta$ -lactamases

in S. Give and S. Heidelberg in Venezuela. This represents a starting point for the development of surveillance programs aimed at the detection of ESBL and PMQR.

## 5. Conclusion

This study highlights the circulation of PMQR determinant *qnrB19* associated with *bla*<sub>TEM-1</sub>, *bla*<sub>SHV-12</sub>, and *bla*<sub>CTX-M-2</sub> in S. Give and S. Heidelberg from pediatric patients and raw chicken meat in Venezuela. The emergence of the combination of PMQR genes with ESBLs may contribute to the appearance of MDR *Salmonella* and jeopardize the usage of valuable antibiotics. We hope that recognition of factors associated with increasing resistance and the study of the molecular mechanisms involved can lead to a more focused use of antimicrobial agents which, in turn, will reduce the selection and spread of PMQR determinants and/or ESBL-producing enteropathogens.

## Conflict of Interests

No conflict of interests is declared by the authors.

## Acknowledgments

This study was partially supported by Consejo de Desarrollo Científico, Humanístico y Tecnológico (CDCHT-ULA) of The Andes University (grant CVI-ADG-FA-02-97-07) and Fondo Nacional de Ciencia, Tecnología e Innovación (FONACIT), Venezuela (grant 2012002321; contracto no. 201201213).

## References

- [1] K. Veldman, C. Dierikx, A. van Essen-Zandbergen, W. van Pelt, and D. Mevius, "Characterization of multidrug-resistant, *qnrB2*-positive and extended-spectrum- $\beta$ -lactamase-producing *Salmonella* concord and *Salmonella* Senftenberg isolates," *Journal of Antimicrobial Chemotherapy*, vol. 65, no. 5, Article ID dkq049, pp. 872–875, 2010.
- [2] A. García-Fernández, D. Fortini, K. Veldman, D. Mevius, and A. Carattoli, "Characterization of plasmids harbouring *qnrSI*, *qnrB2* and *qnrB19* genes in *Salmonella*," *Journal of Antimicrobial Chemotherapy*, vol. 63, no. 2, pp. 274–281, 2009.
- [3] M. Gunell, M. A. Webber, P. Kotilainen et al., "Mechanisms of resistance in nontyphoidal *Salmonella enterica* strains exhibiting a nonclassical quinolone resistance phenotype," *Antimicrobial Agents and Chemotherapy*, vol. 53, no. 9, pp. 3832–3836, 2009.
- [4] L. Crémet, N. Caroff, S. Dauvergne, A. Reynaud, D. Lepelletier, and S. Corvec, "Prevalence of plasmid-mediated quinolone resistance determinants in ESBL Enterobacteriaceae clinical isolates over a 1-year period in a French hospital," *Pathologie Biologie*, vol. 59, no. 3, pp. 151–156, 2011.
- [5] L. M. Glenn, R. L. Lindsey, J. P. Folster et al., "Antimicrobial resistance genes in multidrug-resistant *Salmonella enterica* isolate from animals, retail meats, and humans in the United States and Canada," *Microbial Drug Resistance*, vol. 19, no. 3, pp. 175–184, 2013.
- [6] J. Strahilevitz, G. A. Jacoby, D. C. Hooper, and A. Robicsek, "Plasmid-mediated quinolone resistance: a multifaceted threat," *Clinical Microbiology Reviews*, vol. 22, no. 4, pp. 664–689, 2009.
- [7] J. Ruiz, M. J. Pons, and C. Gomes, "Transferable mechanisms of quinolone resistance," *International Journal of Antimicrobial Agents*, vol. 40, no. 3, pp. 196–203, 2012.
- [8] X. Guan, X. Xue, Y. Liu et al., "Plasmid-mediated quinolone resistance—current knowledge and future perspectives," *Journal of International Medical Research*, vol. 41, no. 1, pp. 20–30, 2013.
- [9] M. O. Pérez-Moreno, E. Picó-Plana, M. de Toro et al., " $\beta$ -lactamases, transferable quinolone resistance determinants, and class 1 integron-mediated antimicrobial resistance in human clinical *Salmonella enterica* isolates of non-typhimurium serotypes," *International Journal of Medical Microbiology*, vol. 303, no. 1, pp. 25–31, 2013.
- [10] F. González, L. Pallecchi, G. M. Rossolini, and M. Araque, "Plasmid-mediated quinolone resistance determinant *qnrB19* in non-typhoidal *Salmonella enterica* strains isolated in Venezuela," *Journal of Infection in Developing Countries*, vol. 6, no. 5, pp. 462–464, 2012.
- [11] M. Araque, "Nontyphoid *Salmonella* gastroenteritis in pediatric patients from urban areas in the city of Mérida, Venezuela," *Journal of Infection in Developing Countries*, vol. 3, no. 1, pp. 28–34, 2009.
- [12] Clinical and Laboratory Standards Institute, "Performance standards for antimicrobial susceptibility test, 23th informational supplement," CLSI Document M100-S23, Wayne, Pa, USA, 2013.
- [13] D. J. Eaves, L. Randall, D. T. Gray et al., "Prevalence of mutations within the quinolone resistance-determining region of *gyrA*, *gyrB*, *parC*, and *parE* and association with antibiotic resistance in quinolone-resistant *Salmonella enterica*," *Antimicrobial Agents and Chemotherapy*, vol. 48, no. 10, pp. 4012–4015, 2004.
- [14] V. Cattoir, F. Weill, L. Poirel, L. Fabre, C. Soussy, and P. Nordmann, "Prevalence of *qnr* genes in *Salmonella* in France," *Journal of Antimicrobial Chemotherapy*, vol. 59, no. 4, pp. 751–754, 2007.
- [15] K. Yamane, J. Wachino, S. Suzuki, and Y. Arakawa, "Plasmid-mediated *qepA* gene among *Escherichia coli* clinical isolates from Japan," *Antimicrobial Agents and Chemotherapy*, vol. 52, no. 4, pp. 1564–1566, 2008.
- [16] L. Pallecchi, A. Bartoloni, C. Fiorelli et al., "Rapid dissemination and diversity of CTX-M extended-spectrum  $\beta$ -lactamase genes in commensal *Escherichia coli* isolates from healthy children from low-resource settings in Latin America," *Antimicrobial Agents and Chemotherapy*, vol. 51, no. 8, pp. 2720–2725, 2007.
- [17] J. Sambrook and D. W. Russell, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 3rd edition, 2001.
- [18] C. Mata, R. Oropeza, and M. Araque, "Patrones de resistencia y presencia de integrones de clase 1 en cepas de *Salmonella enterica* aisladas de pacientes pediátricos provenientes de varias regiones de Venezuela," *Revista de la Facultad de Farmacia*, vol. 49, no. 2, pp. 2–8, 2007.
- [19] J. Velasco, F. González, T. Díaz, J. Peña-Guillén, and M. Araque, "Profiles of enteropathogens in asymptomatic children from indigenous communities of Mérida, Venezuela," *Journal of Infection in Developing Countries*, vol. 5, no. 4, pp. 278–285, 2011.
- [20] N. Molina, B. Millán, and M. Araque, "Indicadores de calidad sanitaria y fenotipificación de *Salmonella enterica* aislada en

- pollo crudo comercializado en supermercados del área urbana del estado Mérida, Venezuela,” *Infectio*, vol. 14, no. 3, pp. 174–185, 2010.
- [21] Y. Chen, T. Liao, Y. Liu, T. Lauderdale, J. Yan, and S. Tsai, “Mobilization of *qnrB2* and ISCR1 in plasmids,” *Antimicrobial Agents and Chemotherapy*, vol. 53, no. 3, pp. 1235–1237, 2009.
- [22] L. Poirel, V. Cattoir, and P. Nordmann, “Plasmid-mediated quinolone resistance, interactions between human, animal, and environmental ecologies,” *Frontiers in Microbiology*, vol. 3, article 24, 2012.
- [23] L. M. Cavaco and F. M. Aarestrup, “Evaluation of quinolones for use in detection of determinants of acquired quinolone resistance, including the new transmissible resistance mechanisms *qnrA*, *qnrB*, *qnrS*, and *aac(6′)Ib-cr*, in *Escherichia coli* and *Salmonella enterica* and determinations of wild-type distributions,” *Journal of Clinical Microbiology*, vol. 47, no. 9, pp. 2751–2758, 2009.
- [24] K. Veldman, L. M. Cavaco, D. Mevius et al., “International collaborative study on the occurrence of plasmid-mediated quinolone resistance in *Salmonella enterica* and *Escherichia coli* isolated from animals, humans, food and the environment in 13 European countries,” *Journal of Antimicrobial Chemotherapy*, vol. 66, no. 6, Article ID dkr084, pp. 1278–1286, 2011.
- [25] R. G. Ferrari, A. Galiana, R. Cremades et al., “Plasmid-mediated quinolone resistance by genes *qnrA1* and *qnrB19* in *Salmonella* strains isolated in Brazil,” *Journal of Infection in Developing Countries*, vol. 5, no. 6, pp. 496–498, 2011.



**Hindawi**

Submit your manuscripts at  
<http://www.hindawi.com>

